CSIMarket
 
Neumora Therapeutics Inc   (NASDAQ: NMRA)
Other Ticker:  
 
 
Price: $2.1200 $-0.04 -1.852%
Day's High: $2.18 Week Perf: 3.41 %
Day's Low: $ 2.08 30 Day Perf: -80.46 %
Volume (M): 3,253 52 Wk High: $ 21.00
Volume (M$): $ 6,896 52 Wk Avg: $11.73
Open: $2.18 52 Wk Low: $1.83



 Market Capitalization (Millions $) 338
 Shares Outstanding (Millions) 160
 Employees 100
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -132
 Cash Flow (TTM) (Millions $) -137
 Capital Exp. (TTM) (Millions $) 0

Neumora Therapeutics Inc
Neumora Therapeutics Inc is a pharmaceutical company that specializes in the development of innovative therapies and treatments for respiratory diseases. The company is focused on finding new approaches to address the unmet medical needs of patients suffering from conditions such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.

Neumora Therapeutics aims to improve patients' quality of life by developing novel drug candidates that target specific mechanisms and pathways involved in respiratory diseases. The company's research and development efforts involve identifying and testing new molecules, conducting preclinical and clinical trials, and seeking regulatory approvals for their products.

With a team of experienced scientists, researchers, and healthcare professionals, Neumora Therapeutics is dedicated to advancing the field of respiratory medicine. They collaborate with leading academic institutions and other industry partners to accelerate the discovery and development process.

In addition to drug development, Neumora Therapeutics also prioritizes patient education and engagement. They are committed to increasing awareness about respiratory diseases, their symptoms, and available treatment options, thereby contributing to better care and management of these conditions.

Overall, Neumora Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for respiratory diseases with the goal of improving the lives of patients.


   Company Address: 490 Arsenal Way Watertown 2472 MA
   Company Phone Number: 760-0900   Stock Exchange / Ticker: NASDAQ NMRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN     
BIIB     
EXEL     
GILD     
HALO     
NBIX     
• View Complete Report
   



Clinical Study

Neumora Therapeutics KOASTAL-1 Study of Navacaprant Under Increased Competitive Pressure

Published Fri, Jan 3 2025 7:42 PM UTC

Abstract: Neumora Therapeutics Inc. has recently released the findings from its KOASTAL-1 study, which evaluated the efficacy of Navacaprant as a treatment for Major Depressive Disorder (MDD). The study, however, did not meet its primary endpoint of demonstrating statistically significant improvement in depressive symptoms as measured by the Montgomery-?sberg Depression Rati...

Clinical Study

Neumora Therapeutics Advances Brain Disease Programs with Exciting Initiatives and Promising Drug Candidates

Published Thu, Jun 20 2024 11:00 AM UTC

Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain diseases, has recently made significant progress in its mission. The company announced the initiation of a Phase 1b study for NMRA-511, a potential breakthrough treatment for Alzheimer s disease agitation. Additionally, the company revealed the clearance of ...

Clinical Study

Neumora Therapeutics Spearheads New Phase in Bipolar Depression and Schizophrenia Treatment with Navacaprant and NMRA-266

Published Tue, May 14 2024 11:00 AM UTC

Neumora Therapeutics, a renowned pharmaceutical company, has made significant strides towards developing innovative treatments for bipolar depression and schizophrenia. After a series of research success, the company recently announced the initiation of a Phase 2 trial for Navacaprant, an advanced therapeutic drug focused on treating bipolar depression, exhibiting potential ...

Clinical Study

Neumora Therapeutics, Inc. to Contribute to Major Investor Conferences in May: A Dive Into Its Promising Brain Disease Therapeutics Pipeline

Published Mon, May 6 2024 11:00 AM UTC

In an exciting development in the pharmaceutical sphere, Neumora Therapeutics, Inc. (Nasdaq: NMRA), a prominent clinical-stage biopharmaceutical company, has recently publicized its plans to participate in a series of leading investor conferences in May.Finding its home base in Watertown, Massachusetts, Neumora Therapeutics is garnering substantial attention, primarily due t...

Clinical Study

Neumora Therapeutics Breaks New Ground in Schizophrenia Treatment with Exciting Phase 1 Clinical Study for NMRA-266, a Promising M4 Muscarinic Receptor Modulator!

Published Mon, Nov 27 2023 12:00 PM UTC

Neumora Therapeutics Initiates Promising Clinical Study for Schizophrenia Treatment with Novel M4 Muscarinic Receptor Modulator
Neumora Therapeutics, a renowned pharmaceutical company known for its innovative approaches in developing effective treatments for mental health disorders, has recently announced the initiation of a groundbreaking Phase 1 clinical study for NMRA...






  Neumora Therapeutics Inc Outlook

On May 7 2024 the Neumora Therapeutics Inc provided following guidance

Neumora Therapeutics Inc. has released their financial results for the fi...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com